The following is a summary of “Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis,” published in the January 2025 issue of Psychiatry by Fountoulakis et al.
Medicaid in Wisconsin has expanded to cover ketamine infusions as of Jan. 1, sparking conversations about the nuances in type ...
The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
Ketamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with ...
( MENAFN - EIN Presswire) Spravato® (esketamine) has been approved for use as a standalone treatment for depression, without the requirement of an accompanying antidepressant. Legal Disclaimer: ...
Hosted on MSN14d
FDA approves 'ketamine' nasal spray for depression — here's everything you need to knowA nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe ...
That's still possible but no longer required.) For treatment-resistant depression, patients usually get the esketamine nasal spray twice a week for one to four weeks. Then they take it once a week ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback